SCHEMBL16600320

SCHEMBL16600320

CC(O)CCC(O)C(O)C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.43
TP53 P04637 1/20 0.41
PDE4A P27815 1/20 0.39
PGD P52209 1/20 0.39
ALDH1A1 P00352 2/20 0.37
GABRR1 P24046 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.34
CHRM1 P11229 1/20 0.33
AKR1A1 P14550 1/20 0.33
CHRM3 P20309 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
ADRA1A P35348 1/20 0.33
HRH1 P35367 1/20 0.33
DRD3 P35462 1/20 0.33
SLC6A3 Q01959 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16600087 0.77 TSHR (0.45) TSHRTP53PDE4APGDCYP2C9
SCHEMBL260456 0.77 CHRM1 (0.52) TSHRPDE4APGDCHRM1AKR1A1
SCHEMBL26138077 0.77 TET2 (0.50) TSHRPDE4APGDCYP2C9
SCHEMBL10535143 0.77 CHRM1 (0.52) TSHRPDE4APGDCHRM1AKR1A1
SCHEMBL10535132 0.77 CHRM1 (0.52) TSHRPDE4APGDCHRM1AKR1A1
SCHEMBL6381204 0.76 GABRR1 (0.59) TP53ALDH1A1GABRR1CYP1A2
SCHEMBL19815026 0.76 TP53 (0.47) TP53ALDH1A1GABRR1CYP1A2CHRM1
SCHEMBL4140782 0.74 TET2 (0.52) TP53ALDH1A1GABRR1CYP1A2
SCHEMBL2784989 0.74 PDE4A (0.48) TSHRPDE4APGDALDH1A1CYP2C9
SCHEMBL16600446 0.73 PDE4A (0.48) TSHRPDE4APGDALDH1A1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250127925-A1 DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO HERCULES CAPITAL, INC. 2025-04-24 US disclosed
US-12076418-B2 Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo ENGENE, INC. (CA) 2024-09-03 US disclosed
US-20220133907-A1 DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO HERCULES CAPITAL, INC. 2022-05-05 US disclosed
EP-3970697-A1 DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO Engene, Inc. (CA) 2022-03-23 EP disclosed
US-11167045-B2 Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo HERCULES CAPITAL, INC. 2021-11-09 US disclosed
EP-3049473-B1 DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO ENGENE INC (CA) 2021-09-22 EP disclosed
US-20200061208-A1 DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO HERCULES CAPITAL, INC. 2020-02-27 US disclosed
US-10456481-B2 Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo HERCULES CAPITAL, INC. 2019-10-29 US disclosed
US-20180344875-A1 DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO HERCULES CAPITAL, INC. 2018-12-06 US disclosed
US-20160235863-A1 DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO HERCULES CAPITAL, INC. 2016-08-18 US disclosed
EP-3049473-A1 DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO Engene, Inc. (CA) 2016-08-03 EP disclosed
WO-2015042711-A1 DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO ENGENE, INC. (CA) 2015-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200061208-A1 DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO CSGALNACT1, CHI3L2, LNPEP TSHR 4331/4885TP53 1908/4885PDE4A 4587/4885
US-20180344875-A1 DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO CSGALNACT1, CHI3L2, LNPEP TSHR 4331/4885TP53 1908/4885PDE4A 4587/4885
US-20250127925-A1 DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO CSGALNACT1, CHI3L2, LNPEP TSHR 4331/4885TP53 1908/4885PDE4A 4587/4885
US-11167045-B2 Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo CSGALNACT1, CHI3L2, LNPEP TSHR 4331/4885TP53 1908/4885PDE4A 4587/4885
US-12076418-B2 Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo CSGALNACT1, CHI3L2, LNPEP TSHR 4331/4885TP53 1908/4885PDE4A 4587/4885
US-10456481-B2 Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo CSGALNACT1, CHI3L2, LNPEP TSHR 4331/4885TP53 1908/4885PDE4A 4587/4885
US-20160235863-A1 DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO CSGALNACT1, CHI3L2, LNPEP TSHR 4331/4885TP53 1908/4885PDE4A 4587/4885
US-20220133907-A1 DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO CSGALNACT1, CHI3L2, LNPEP TSHR 4331/4885TP53 1908/4885PDE4A 4587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.